Thousands of women in England gain access to life-extending breast cancer drug
About 1,000 women a year with incurable HER2-low breast cancer in England will receive Enhertu on the NHS starting Thursday after a successful price deal.
NICE approves routine use of drug
The National Institute for Health and Care Excellence recommended Enhertu for routine use on Thursday. This decision follows previous rejection in July 2024 because officials deemed the cost too high. Ministers and the drug makers struck a deal on price to enable access.
Clinical trials show survival gains
Clinical trials showed that Enhertu almost doubled median progression-free survival from 5.1 months to 9.9 months compared with normal chemotherapy. Median overall survival was 23.4 months for users versus 16.8 months for those not on the treatment. This represents a gain of 6.6 months in life expectancy.
Campaigners celebrate milestone victory
Claire Rowney, chief executive of Breast Cancer Now, called the event a momentous day for thousands of patients. She stated the drug gives people an opportunity to gain precious time with loved ones. The charity led two years of determined campaigning alongside cancer specialists and women.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.